Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis For Up to 3 Years: An Open-Label Extension of Randomized Clinical Trials
Related Posts
Dirr MA, Ahmed A, Schlessinger DI, Lazaro-Camp V, Smith S, Gullapalli T, Dragovic D, Chang J, Zhang E, Alam M; Facial Aging Core Outcome Domain[...]
To TT, Deng M, Andrade PR, Nguyen NPN, Brewer GM, Hu C, Agak GW. Cutibacterium acnes induce T cell extracellular traps with distinct proteome programs.[...]
Armstrong AW, Bin Sawad A, Hazra NC, Balu S, Maslin D, Libchaber B, Huang R, Gauthier-Loiselle M, Guerin A. Patient Preferences for Treatment Attributes in[...]